CenterBook Partners LP Purchases Shares of 25,995 Azenta, Inc. $AZTA

CenterBook Partners LP bought a new position in shares of Azenta, Inc. (NASDAQ:AZTA) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 25,995 shares of the company’s stock, valued at approximately $865,000. CenterBook Partners LP owned about 0.06% of Azenta at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Assetmark Inc. grew its position in shares of Azenta by 54.1% during the fourth quarter. Assetmark Inc. now owns 832 shares of the company’s stock worth $28,000 after acquiring an additional 292 shares during the last quarter. Osaic Holdings Inc. grew its position in shares of Azenta by 44.9% during the second quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after acquiring an additional 385 shares during the last quarter. CWM LLC grew its position in shares of Azenta by 27.3% during the fourth quarter. CWM LLC now owns 1,822 shares of the company’s stock worth $61,000 after acquiring an additional 391 shares during the last quarter. Neuberger Berman Group LLC grew its position in shares of Azenta by 6.2% during the third quarter. Neuberger Berman Group LLC now owns 7,695 shares of the company’s stock worth $221,000 after acquiring an additional 451 shares during the last quarter. Finally, Empowered Funds LLC lifted its holdings in shares of Azenta by 10.5% during the first quarter. Empowered Funds LLC now owns 6,482 shares of the company’s stock worth $225,000 after purchasing an additional 618 shares during the period. 99.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on AZTA. Needham & Company LLC decreased their price target on Azenta from $44.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $39.50.

Azenta Trading Down 1.5%

Azenta stock opened at $22.38 on Thursday. The stock has a market cap of $1.03 billion, a PE ratio of -5.65 and a beta of 1.39. The stock has a 50-day moving average price of $21.95 and a 200 day moving average price of $28.33. Azenta, Inc. has a 52 week low of $15.93 and a 52 week high of $41.73.

Azenta (NASDAQ:AZTA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). The firm had revenue of $144.80 million for the quarter, compared to analysts’ expectations of $148.47 million. Azenta had a positive return on equity of 1.23% and a negative net margin of 30.49%.The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.01 EPS.

Azenta Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.